

# Mark Bolland

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7403356/publications.pdf>

Version: 2024-02-01

271  
papers

13,507  
citations

36691

53  
h-index

27587

110  
g-index

282  
all docs

282  
docs citations

282  
times ranked

12899  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. <i>BMJ: British Medical Journal</i> , 2010, 341, c3691-c3691.	2.4	931
2	Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. <i>BMJ: British Medical Journal</i> , 2011, 342, d2040-d2040.	2.4	740
3	Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2008, 336, 262-266.	2.4	585
4	Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. <i>Lancet, The</i> , 2014, 383, 146-155.	6.3	497
5	A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. <i>European Journal of Endocrinology</i> , 2008, 159, 89-95.	1.9	409
6	The Peroxisome Proliferator-Activated Receptor- $\beta$ Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1305-1310.	1.8	399
7	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 307-320.	5.5	371
8	Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. <i>Bone</i> , 2007, 41, 318-320.	1.4	332
9	Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2017, 359, j4849.	2.4	320
10	Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 847-858.	5.5	303
11	Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1174-1181.	1.8	285
12	Fracture Prevention with Zoledronate in Older Women with Osteopenia. <i>New England Journal of Medicine</i> , 2018, 379, 2407-2416.	13.9	280
13	Calcium intake and bone mineral density: systematic review and meta-analysis. <i>BMJ, The</i> , 2015, 351, h4183.	3.0	272
14	Randomized Controlled Trial of Calcium in Healthy Older Women. <i>American Journal of Medicine</i> , 2006, 119, 777-785.	0.6	249
15	Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 1144-1149.	2.2	243
16	Calcium intake and risk of fracture: systematic review. <i>BMJ, The</i> , 2015, 351, h4580.	3.0	241
17	Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. <i>American Journal of Clinical Nutrition</i> , 2014, 100, 746-755.	2.2	229
18	Association between Primary Hyperparathyroidism and Increased Body Weight: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1525-1530.	1.8	183

#	ARTICLE	IF	CITATIONS
19	The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. <i>American Journal of Clinical Nutrition</i> , 2007, 86, 959-964.	2.2	173
20	Evaluation of the FRAX and Garvan fracture risk calculators in older women. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 420-427.	3.1	158
21	Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 569-576.	5.5	151
22	Mortality and morbidity in Cushing's syndrome in New Zealand. <i>Clinical Endocrinology</i> , 2011, 75, 436-442.	1.2	149
23	Vitamin D supplementation and falls: a trial sequential meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 573-580.	5.5	149
24	Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. <i>Bone</i> , 2006, 38, 317-321.	1.4	126
25	Randomized Controlled Trial of Calcium Supplementation in Healthy, Nonosteoporotic, Older Men. <i>Archives of Internal Medicine</i> , 2008, 168, 2276.	4.3	122
26	Determinants of vitamin D status in older women living in a subtropical climate. <i>Osteoporosis International</i> , 2005, 16, 1641-1648.	1.3	121
27	Annual Zoledronate Increases Bone Density in Highly Active Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Men: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1283-1288.	1.8	119
28	Vitamin D insufficiency and health outcomes over 5 y in older women. <i>American Journal of Clinical Nutrition</i> , 2010, 91, 82-89.	2.2	119
29	Low Body Weight Mediates the Relationship between HIV Infection and Low Bone Mineral Density: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4522-4528.	1.8	118
30	The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. <i>Osteoporosis International</i> , 2007, 18, 479-486.	1.3	115
31	Effect of calcium supplementation on hip fractures. <i>Osteoporosis International</i> , 2008, 19, 1119-1123.	1.3	111
32	The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. <i>Diabetologia</i> , 2015, 58, 2238-2246.	2.9	104
33	Calcium supplements: benefits and risks. <i>Journal of Internal Medicine</i> , 2015, 278, 354-368.	2.7	101
34	The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 538-544.	1.8	100
35	Effects of a $\beta$ -Blocker on Bone Turnover in Normal Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5212-5216.	1.8	97
36	Circulating calcium concentrations, vascular disease and mortality: a systematic review. <i>Journal of Internal Medicine</i> , 2016, 279, 524-540.	2.7	97

#	ARTICLE	IF	CITATIONS
37	Cardiovascular effects of calcium supplementation. <i>Osteoporosis International</i> , 2011, 22, 1649-1658.	1.3	93
38	Systematic review and statistical analysis of the integrity of 33 randomized controlled trials. <i>Neurology</i> , 2016, 87, 2391-2402.	1.5	92
39	Effects of calcium supplementation on lipids, blood pressure, and body composition in healthy older men: a randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2010, 91, 131-139.	2.2	91
40	Cushing's Syndrome Due to Interaction Between Inhaled Corticosteroids and Itraconazole. <i>Annals of Pharmacotherapy</i> , 2004, 38, 46-49.	0.9	90
41	Skeletal Effects of Interventions in Mild Primary Hyperparathyroidism: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1653-1662.	1.8	85
42	Relationships between vascular calcification, calcium metabolism, bone density, and fractures. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2777-2785.	3.1	83
43	Five years of anti-resorptive activity after a single dose of zoledronate " Results from a randomized double-blind placebo-controlled trial. <i>Bone</i> , 2012, 50, 1389-1393.	1.4	83
44	Calcium supplements and cancer risk: a meta-analysis of randomised controlled trials. <i>British Journal of Nutrition</i> , 2013, 110, 1384-1393.	1.2	81
45	Calcium and Cardiovascular Disease. <i>Endocrinology and Metabolism</i> , 2017, 32, 339.	1.3	75
46	Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 505-512.	3.1	74
47	Age-, gender-, and weight-related effects on levels of 25-hydroxyvitamin D are not mediated by vitamin D binding protein. <i>Clinical Endocrinology</i> , 2007, 67, 259-264.	1.2	73
48	Delayed Development of Paget's Disease in Offspring Inheriting SQSTM1 Mutations. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 411-415.	3.1	73
49	Does calcium supplementation increase cardiovascular risk?. <i>Clinical Endocrinology</i> , 2010, 73, 689-695.	1.2	73
50	Determinants of vitamin D status in older men living in a subtropical climate. <i>Osteoporosis International</i> , 2006, 17, 1742-1748.	1.3	70
51	Stable Bone Density in HAART-Treated Individuals with HIV: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2721-2731.	1.8	68
52	Check for publication integrity before misconduct. <i>Nature</i> , 2020, 577, 167-169.	13.7	64
53	Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2251-2255.	3.1	57
54	Role of ultrasound in the assessment of nodular thyroid disease. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2009, 53, 177-187.	0.9	55

#	ARTICLE	IF	CITATIONS
55	Calcium supplements and cardiovascular risk: 5 years on. <i>Therapeutic Advances in Drug Safety</i> , 2013, 4, 199-210.	1.0	55
56	Calcium supplementation in osteoporosis: useful or harmful?. <i>European Journal of Endocrinology</i> , 2018, 178, D13-D25.	1.9	55
57	Decreased bone density in men on methadone maintenance therapy. <i>Addiction</i> , 2011, 106, 349-354.	1.7	53
58	Differences in Overlapping Meta-Analyses of Vitamin D Supplements and Falls. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4265-4272.	1.8	53
59	Paget disease of bone. <i>Trends in Endocrinology and Metabolism</i> , 2008, 19, 246-253.	3.1	52
60	Unhelpful information about adverse drug reactions. <i>BMJ, The</i> , 2014, 349, g5019-g5019.	3.0	52
61	Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least Five Years in HIV-Infected Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1922-1928.	1.8	50
62	Mendelian Randomization Analysis to Examine for a Causal Effect of Urate on Bone Mineral Density. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 985-991.	3.1	50
63	Bone mineral density remains stable in HAART-treated HIV-infected men over 2Âyears. <i>Clinical Endocrinology</i> , 2007, 67, 270-275.	1.2	49
64	Clinical Trial Evidence and Use of Fish Oil Supplements. <i>JAMA Internal Medicine</i> , 2014, 174, 460.	2.6	49
65	Trials of Vertebroplasty for Vertebral Fractures. <i>New England Journal of Medicine</i> , 2009, 361, 2097-2100.	13.9	47
66	Paget's disease of bone: clinical review and update. <i>Journal of Clinical Pathology</i> , 2013, 66, 924-927.	1.0	47
67	A Case Study of Discordant Overlapping Meta-Analyses: Vitamin D Supplements and Fracture. <i>PLoS ONE</i> , 2014, 9, e115934.	1.1	47
68	Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. <i>Clinical Endocrinology</i> , 2006, 65, 191-197.	1.2	45
69	The effect of treatments for osteoporosis on mortality. <i>Osteoporosis International</i> , 2013, 24, 1-6.	1.3	45
70	Should we prescribe calcium or vitamin D supplements to treat or prevent osteoporosis?. <i>Climacteric</i> , 2015, 18, 22-31.	1.1	44
71	The effects of seasonal variation of 25-hydroxyvitamin D on diagnosis of vitamin D insufficiency. <i>New Zealand Medical Journal</i> , 2008, 121, 63-74.	0.5	44
72	Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial. <i>European Journal of Endocrinology</i> , 2012, 166, 1087-1091.	1.9	43

#	ARTICLE	IF	CITATIONS
73	Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 286-292.	1.8	43
74	Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues?. <i>Osteoporosis International</i> , 2014, 25, 2347-2357.	1.3	43
75	Controversies in medicine: the role of calcium and vitamin D supplements in adults. <i>Medical Journal of Australia</i> , 2019, 211, 468-473.	0.8	43
76	Calcium and/or Vitamin D Supplementation for the Prevention of Fragility Fractures: Who Needs It?. <i>Nutrients</i> , 2020, 12, 1011.	1.7	43
77	Effects of Intravenous Zoledronate on Bone Turnover and BMD Persist for at Least 24 Months. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1304-1308.	3.1	41
78	Reporting of Limitations of Observational Research. <i>JAMA Internal Medicine</i> , 2015, 175, 1571.	2.6	39
79	Role of vitamin D deficiency in cardiovascular disease. <i>Heart</i> , 2012, 98, 609-614.	1.2	38
80	The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. <i>European Journal of Endocrinology</i> , 2014, 170, 255-262.	1.9	37
81	Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial. <i>Osteoporosis International</i> , 2015, 26, 499-503.	1.3	37
82	Disparate Outcomes from Applying U.K. and U.S. Osteoporosis Treatment Guidelines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1856-1860.	1.8	36
83	Calcium supplements: bad for the heart?. <i>Heart</i> , 2012, 98, 895-896.	1.2	36
84	Skeletal health in adults with HIV infection. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 63-74.	5.5	36
85	An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature. <i>BMJ Open</i> , 2019, 9, e031909.	0.8	36
86	Calcium supplementation: Balancing the cardiovascular risks. <i>Maturitas</i> , 2011, 69, 289-295.	1.0	34
87	Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. <i>Cmaj</i> , 2017, 189, E1130-E1136.	0.9	34
88	Randomised controlled trial of vitamin D supplementation in sarcoidosis. <i>BMJ Open</i> , 2013, 3, e003562.	0.8	33
89	Antioxidant supplements for preventing gastrointestinal cancers. , 2004, , CD004183.		31
90	Antiretroviral Preexposure Prophylaxis for HIV Prevention. <i>New England Journal of Medicine</i> , 2013, 368, 82-84.	13.9	31

#	ARTICLE	IF	CITATIONS
91	Calcium riskâ€“benefit updatedâ€”New WHI analyses. <i>Maturitas</i> , 2014, 77, 1-3.	1.0	31
92	Citation of retracted publications: A challenging problem. <i>Accountability in Research</i> , 2022, 29, 18-25.	1.6	31
93	A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record. <i>BMJ Open</i> , 2014, 4, e005787.	0.8	30
94	Cardiovascular Complications of Calcium Supplements. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 494-501.	1.2	30
95	Discrepancies in predicted fracture risk in elderly people. <i>BMJ, The</i> , 2013, 346, e8669-e8669.	3.0	28
96	Should adults take vitamin D supplements to prevent disease?. <i>BMJ, The</i> , 2016, 355, i6201.	3.0	28
97	Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1641-e1647.	1.8	28
98	Heterophile antibodies may cause falsely lowered serum cortisol values. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 643-645.	1.8	27
99	Web of industry, advocacy, and academia in the management of osteoporosis. <i>BMJ, The</i> , 2015, 351, h3170.	3.0	27
100	Assessment of research waste part 2: wrong study populations- an exemplar of baseline vitamin D status of participants in trials of vitamin D supplementation. <i>BMC Medical Research Methodology</i> , 2018, 18, 101.	1.4	27
101	The effect of calcium supplementation on serum urate: analysis of a randomized controlled trial. <i>Rheumatology</i> , 2008, 48, 195-197.	0.9	26
102	Evolution of Paget's disease of bone in adults inheriting <i>SCN1A</i> mutations. <i>Clinical Endocrinology</i> , 2015, 83, 315-319.	1.2	26
103	The Auckland calcium study: 5-year post-trial follow-up. <i>Osteoporosis International</i> , 2014, 25, 297-304.	1.3	25
104	Stable bone mineral density over 6â€“years in HIVâ€“infected men treated with highly active antiretroviral therapy (HAART). <i>Clinical Endocrinology</i> , 2012, 76, 643-648.	1.2	24
105	Meta-analysis of randomised trials comparing a penicillin or cephalosporin with a macrolide or lincosamide in the treatment of cellulitis or erysipelas. <i>Infection</i> , 2016, 44, 607-615.	2.3	23
106	Quality of reports of investigations of research integrity by academic institutions. <i>Research Integrity and Peer Review</i> , 2019, 4, 3.	2.2	23
107	Bone Formation Markers in Adults with Mild Osteogenesis Imperfecta. <i>Clinical Chemistry</i> , 2007, 53, 1109-1114.	1.5	22
108	Calcium supplementation and vascular disease. <i>Climacteric</i> , 2008, 11, 280-286.	1.1	22

#	ARTICLE	IF	CITATIONS
109	Duration of Antiresorptive Effects of Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo-Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 166-172.	3.1	21
110	Ten years too long: strontium ranelate, cardiac events, and the European Medicines Agency. <i>BMJ</i> , The, 2016, 354, i5109.	3.0	21
111	Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial. <i>Journal of Internal Medicine</i> , 2019, 286, 221-229.	2.7	21
112	Results of Observational Studies: Analysis of Findings from the Nurses' Health Study. <i>PLoS ONE</i> , 2014, 9, e110403.	1.1	21
113	The impact of dietary calcium intake and vitamin D status on the effects of zoledronate. <i>Osteoporosis International</i> , 2013, 24, 349-354.	1.3	20
114	Low-dose Fluoride in Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2301-2307.	1.8	20
115	A case of low cortisol-binding globulin: use of plasma free cortisol in interpretation of hypothalamic-pituitary-adrenal axis tests. <i>Annals of Clinical Biochemistry</i> , 2006, 43, 237-239.	0.8	19
116	Does degree of baldness influence vitamin D status?. <i>Medical Journal of Australia</i> , 2008, 189, 674-675.	0.8	19
117	We read spam a lot: prospective cohort study of unsolicited and unwanted academic invitations. <i>BMJ</i> , The, 2016, 355, i5383.	3.0	19
118	Reporting of conflicts of interest in oral presentations at medical conferences: a delegate-based prospective observational study. <i>BMJ Open</i> , 2017, 7, e017019.	0.8	19
119	Rounding, but not randomization method, non-normality, or correlation, affected baseline P-value distributions in randomized trials. <i>Journal of Clinical Epidemiology</i> , 2019, 110, 50-62.	2.4	18
120	Gastrointestinal stromal tumour in succinate dehydrogenase subunit B mutation-associated familial pheochromocytoma/paraganglioma. <i>ANZ Journal of Surgery</i> , 2006, 76, 763-764.	0.3	17
121	Differences between self-reported and verified adverse cardiovascular events in a randomised clinical trial. <i>BMJ Open</i> , 2013, 3, e002334.	0.8	16
122	Baseline P value distributions in randomized trials were uniform for continuous but not categorical variables. <i>Journal of Clinical Epidemiology</i> , 2019, 112, 67-76.	2.4	16
123	Empirically generated reference proportions for baseline p values from rounded summary statistics. <i>Anaesthesia</i> , 2020, 75, 1685-1687.	1.8	16
124	Bilateral Femoral Head Osteonecrosis After Septic Shock and Multiorgan Failure. <i>Journal of Bone and Mineral Research</i> , 2003, 19, 517-520.	3.1	15
125	Testosterone Levels Following Decreases in Serum Osteocalcin. <i>Calcified Tissue International</i> , 2013, 93, 133-136.	1.5	15
126	Subgroup analysis for the risk of cardiovascular disease with calcium supplements. <i>BoneKey Reports</i> , 2013, 2, 293.	2.7	15



#	ARTICLE	IF	CITATIONS
127	Management recommendations for osteoporosis in clinical guidelines. <i>Clinical Endocrinology</i> , 2016, 84, 687-692.	1.2	15
128	Time for a moratorium on vitamin D meta-analyses?. <i>BMJ: British Medical Journal</i> , 2009, 339, b4394-b4394.	2.4	15
129	Trials of vertebroplasty for vertebral fractures. <i>New England Journal of Medicine</i> , 2009, 361, 2098-9; author reply 2099-100.	13.9	15
130	Artifact in the control group undermines the conclusions of a vitamin D and cancer study. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 792-792.	2.2	14
131	Calcium Supplements Increase Risk of Myocardial Infarction. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 389-390.	3.1	14
132	Assessing and Raising Concerns About Duplicate Publication, Authorship Transgressions and Data Errors in a Body of Preclinical Research. <i>Science and Engineering Ethics</i> , 2020, 26, 2069-2096.	1.7	14
133	Dietary calcium intake and change in bone mineral density in older adults: a systematic review of longitudinal cohort studies. <i>European Journal of Clinical Nutrition</i> , 2022, 76, 196-205.	1.3	14
134	Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 3-11.	3.1	14
135	Familial Paget Disease and SQSTM1 Mutations in New Zealand. <i>Calcified Tissue International</i> , 2011, 89, 258-264.	1.5	13
136	Calcium Supplements and Fracture Prevention. <i>New England Journal of Medicine</i> , 2014, 370, 386-388.	13.9	13
137	Bone density is normal and does not change over 2 years in sarcoidosis. <i>Osteoporosis International</i> , 2015, 26, 611-616.	1.3	13
138	Do vitamin D supplements help prevent respiratory tract infections?. <i>BMJ: British Medical Journal</i> , 2017, 356, j456.	2.4	13
139	Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry. <i>BMJ Open</i> , 2017, 7, e013703.	0.8	13
140	Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least 11 Years in HIV-Infected Men. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1248-1253.	3.1	13
141	Timeliness and content of retraction notices for publications by a single research group. <i>Accountability in Research</i> , 2022, 29, 347-378.	1.6	13
142	Media Coverage, Journal Press Releases and Editorials Associated with Randomized and Observational Studies in High-Impact Medical Journals: A Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0145294.	1.1	13
143	Osteomalacia in an HIV-infected man receiving rifabutin, a cytochrome P450 enzyme inducer: a case report. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2008, 7, 3.	1.7	12
144	Bilateral Transient Osteoporosis of the Hip in a Young Man. <i>Journal of Clinical Densitometry</i> , 2008, 11, 339-341.	0.5	12

#	ARTICLE	IF	CITATIONS
145	Calcium supplementation and cancer incidence. American Journal of Clinical Nutrition, 2008, 87, 792-793.	2.2	12
146	Conflicts of interest and expertise of independent commenters in news stories about medical research. Cmaj, 2017, 189, E553-E559.	0.9	11
147	Publication rates after the first retraction for biomedical researchers with multiple retracted publications. Accountability in Research, 2019, 26, 277-287.	1.6	11
148	Evidence From Randomized Controlled Trials, Meta-analyses, and Subgroup Analyses. JAMA - Journal of the American Medical Association, 2010, 303, 1253.	3.8	10
149	Calcium Supplements and Risk of Myocardial Infarction: An Hypothesis Twice Tested. American Journal of Medicine, 2012, 125, e15.	0.6	10
150	Correcting the scientific record – A broken system?. Accountability in Research, 2021, 28, 265-279.	1.6	10
151	Concordance of Results from Randomized and Observational Analyses within the Same Study: A Re-Analysis of the Women’s Health Initiative Limited-Access Dataset. PLoS ONE, 2015, 10, e0139975.	1.1	10
152	Response to publication of PRISM trial. Journal of Bone and Mineral Research, 2010, 25, 1463-1464.	3.1	9
153	Misclassification does not explain increased cardiovascular risks of calcium supplements. Journal of Bone and Mineral Research, 2012, 27, 959-959.	3.1	9
154	Comment on Kanis et al.: Pitfalls in the external validation of FRAX. Osteoporosis International, 2013, 24, 389-390.	1.3	9
155	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes – Authors' reply. Lancet Diabetes and Endocrinology, 2014, 2, 364-365.	5.5	9
156	Assessment of research waste part 1: an exemplar from examining study design, surrogate and clinical endpoints in studies of calcium intake and vitamin D supplementation. BMC Medical Research Methodology, 2018, 18, 103.	1.4	9
157	Re: The calcium scare: what would Austin Bradford Hill have thought?. Osteoporosis International, 2011, 22, 3079-3080.	1.3	8
158	Calcium supplements and cardiovascular risk. Journal of Bone and Mineral Research, 2011, 26, 899-899.	3.1	8
159	Predictors of Fracture in Older Women With Osteopenic Hip Bone Mineral Density Treated With Zoledronate. Journal of Bone and Mineral Research, 2020, 36, 61-66.	3.1	8
160	Vitamin D supplementation and testing in the UK: costly but ineffective?. BMJ, The, 2021, 372, n484.	3.0	8
161	Calcium supplements and cardiovascular risk. Nature Reviews Cardiology, 2012, 9, 497-498.	6.1	7
162	Calcium Intake and Cardiovascular Disease Risk. Annals of Internal Medicine, 2017, 166, 684.	2.0	7

#	ARTICLE	IF	CITATIONS
163	Further major uncorrected errors in National Osteoporosis Foundation meta-analyses of calcium and vitamin D supplementation in fracture prevention. <i>Osteoporosis International</i> , 2017, 28, 733-734.	1.3	7
164	A randomised investigation of journal responses to academic and journalist enquiry about possible scientific misconduct. <i>BMC Research Notes</i> , 2018, 11, 521.	0.6	7
165	25-Hydroxyvitamin D " Should labs be measuring it?. <i>Annals of Clinical Biochemistry</i> , 2019, 56, 188-189.	0.8	7
166	Participant withdrawals were unusually distributed in randomized trials with integrity concerns: a statistical investigation. <i>Journal of Clinical Epidemiology</i> , 2021, 131, 22-29.	2.4	7
167	Vitamin D Dose Requirements for Fracture Prevention. <i>New England Journal of Medicine</i> , 2012, 367, 1367-1370.	13.9	6
168	Press Releases Issued by Supplements Industry Organisations and Non-Industry Organisations in Response to Publication of Clinical Research Findings: A Case-Control Study. <i>PLoS ONE</i> , 2014, 9, e101533.	1.1	6
169	Nitrates Do Not Affect Bone Density or Bone Turnover in Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1040-1047.	3.1	6
170	Clinical trial registry documents and publication integrity. <i>Accountability in Research</i> , 2021, 28, 149-161.	1.6	6
171	Authors' response to editorial. <i>BMJ: British Medical Journal</i> , 2011, 342, d3520-d3520.	2.4	5
172	Errors in NOF meta-analyses of calcium and vitamin D supplements. <i>Osteoporosis International</i> , 2016, 27, 2637-2639.	1.3	5
173	Identical summary statistics were uncommon in randomized trials and cohort studies. <i>Journal of Clinical Epidemiology</i> , 2021, 136, 180-188.	2.4	5
174	Osteonecrosis of the jaw and bisphosphonates--putting the risk in perspective. <i>New Zealand Medical Journal</i> , 2006, 119, U2339.	0.5	5
175	A randomized trial alerting authors, with or without coauthors or editors, that research they cited in systematic reviews and guidelines has been retracted. <i>Accountability in Research</i> , 2024, 31, 14-37.	1.6	5
176	Effect of calcium supplementation on hip fractures: reply to correspondence. <i>Osteoporosis International</i> , 2009, 20, 835-836.	1.3	4
177	Calcium supplements and cardiovascular risk in the Women's Health Initiative. <i>Osteoporosis International</i> , 2013, 24, 2371-2372.	1.3	4
178	Vitamin D supplements do not reduce mortality risk. <i>BMJ, The</i> , 2014, 348, g2860-g2860.	3.0	4
179	Inconsistent data in text and tables. <i>Osteoporosis International</i> , 2015, 26, 2713-2713.	1.3	4
180	Vitamin D Supplements and the Risk of Falls. <i>JAMA Internal Medicine</i> , 2015, 175, 1723.	2.6	4

#	ARTICLE	IF	CITATIONS
181	Concerns About the Integrity of Sato et al. Am J Med. 2005;118:1250-1255. American Journal of Medicine, 2018, 131, e107-e108.	0.6	4
182	Concerns About the Integrity of the Yamaguchi Osteoporosis Prevention Study (YOPS) Report, Am J Med. 2004;117:549-555. American Journal of Medicine, 2020, 133, e311-e314.	0.6	4
183	Prevalence of biochemical osteomalacia in adults undergoing vitamin D testing. Clinical Endocrinology, 2021, 95, 74-83.	1.2	4
184	Prospective 10-year study of postmenopausal women with asymptomatic primary hyperparathyroidism. New Zealand Medical Journal, 2008, 121, 18-29.	0.5	4
185	Prevalent dietary supplement use in older New Zealand men. New Zealand Medical Journal, 2011, 124, 55-62.	0.5	4
186	Evidence From Randomized Controlled Trials, Meta-analyses, and Subgroup Analyses. JAMA - Journal of the American Medical Association, 2010, 303, 1253.	3.8	3
187	Calcium supplements and cardiovascular disease - picking the spin. International Journal of Clinical Practice, 2011, 65, 226-227.	0.8	3
188	Fracture-risk calculators: Has their time come?. Cmaj, 2011, 183, 171-172.	0.9	3
189	Vitamin D testing. Lancet, The, 2012, 379, 1699.	6.3	3
190	Vitamin D and health in adults in Australia and New Zealand: a position statement. Medical Journal of Australia, 2012, 197, 553-553.	0.8	3
191	A pooled analysis of Vitamin D dose requirements for fracture prevention. IBMS BoneKEy, 2013, 10, .	0.1	3
192	Strontium and cardiovascular events. Annals of the Rheumatic Diseases, 2013, 72, e22-e22.	0.5	3
193	An inappropriate response?. BMJ, The, 2013, 346, f942-f942.	3.0	3
194	Vitamin and Mineral Supplements in the Primary Prevention of Cardiovascular Disease and Cancer. Annals of Internal Medicine, 2014, 160, 655.	2.0	3
195	Different outcomes of meta-analyses and data inconsistency: response to comments by Pfeifer. Archives of Osteoporosis, 2015, 10, 43.	1.0	3
196	Vitamin D supplements do not prevent falls. BMJ, The, 2016, 353, i3005.	3.0	3
197	Cessation of strontium ranelate supply. BMJ: British Medical Journal, 2017, 357, j2580.	2.4	3
198	Outcomes, Interventions and Funding in Randomised Research Published in High-Impact Journals. Trials, 2018, 19, 592.	0.7	3

#	ARTICLE	IF	CITATIONS
199	Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy. <i>Calcified Tissue International</i> , 2019, 105, 423-429.	1.5	3
200	Vitamin D supplementation and musculoskeletal health – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 88-89.	5.5	3
201	"Cherry picking" did not occur in studied example. <i>BMJ: British Medical Journal</i> , 2010, 341, c5009-c5009.	2.4	3
202	The randomised controlled trial to meta-analysis ratio: original data versus systematic reviews in the medical literature. <i>New Zealand Medical Journal</i> , 2007, 120, U2804.	0.5	3
203	Should measurement of vitamin D and treatment of vitamin D insufficiency be routine in New Zealand?. <i>New Zealand Medical Journal</i> , 2012, 125, 83-91.	0.5	3
204	Translation of research into clinical practice: a case study of calcium supplement prescribing in New Zealand. <i>New Zealand Medical Journal</i> , 2014, 127, 94-101.	0.5	3
205	Outcomes of bone density measurements in coeliac disease. <i>New Zealand Medical Journal</i> , 2016, 129, 40-4.	0.5	3
206	Diversity of invited speakers at endocrinology conferences. <i>Clinical Endocrinology</i> , 2022, 96, 907-913.	1.2	3
207	Calcium supplementation for older men and women?. <i>Osteoporosis International</i> , 2009, 20, 2147-2148.	1.3	2
208	Is calcium supplementation a risk factor for cardiovascular diseases in older women?. <i>Nutrition Reviews</i> , 2009, 67, 424-424.	2.6	2
209	Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 514-515.	0.2	2
210	Vitamin D Supplementation. <i>Archives of Internal Medicine</i> , 2010, 170, 572.	4.3	2
211	Vitamin D testing. <i>Lancet, The</i> , 2012, 379, 1699-1700.	6.3	2
212	Vitamin D and tuberculosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3528-E3528.	3.3	2
213	Calcium supplements associated with increased risk of cardiovascular death in men but not women. <i>Evidence-based Nursing</i> , 2014, 17, 90-90.	0.1	2
214	Review: Dietary or supplemental calcium increase BMD by 1.8% in persons >50 years of age. <i>Annals of Internal Medicine</i> , 2016, 164, JC5.	2.0	2
215	News coverage of clinical research. <i>BMJ, The</i> , 2016, 352, i1177.	3.0	2
216	Inaccurate dissemination of the MAVIDOS trial results. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 481.	5.5	2

#	ARTICLE	IF	CITATIONS
217	Qualitative research, observational research, andThe BMJ. BMJ, The, 2016, 352, i1483.	3.0	2
218	Revised Meta-analysis of Vitamin K and Fractures. JAMA Internal Medicine, 2018, 178, 1135.	2.6	2
219	Inaccurate retraction notice for meta-analysis by Iwamoto et al. Acta Neurologica Scandinavica, 2018, 138, 263-263.	1.0	2
220	Population vitamin D supplementation in UK adults: too much of nothing?. Drug and Therapeutics Bulletin, 2021, 59, 7-12.	0.3	2
221	Evaluation and Treatment of Primary Hyperparathyroidism. JAMA - Journal of the American Medical Association, 2005, 294, 2699-2700.	3.8	1
222	Osteonecrosis of the jaw and bisphosphonates. BMJ: British Medical Journal, 2006, 333, 1122.3-1123.	2.4	1
223	Vitamin D sufficiency: reply to letter by Heaney. Osteoporosis International, 2007, 18, 835-836.	1.3	1
224	Calcium supplementation does not increase mortality. Medical Journal of Australia, 2008, 189, 55-56.	0.8	1
225	The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. Obstetrical and Gynecological Survey, 2009, 64, 462-463.	0.2	1
226	Investigating harms in clinical trials - no easy task. International Journal of Clinical Practice, 2010, 64, 1719-1722.	0.8	1
227	Morbidity and mortality in mild primary hyperparathyroidism. Clinical Endocrinology, 2010, 73, 688-688.	1.2	1
228	Reply to RT Chlebowski et al. American Journal of Clinical Nutrition, 2012, 95, 259.	2.2	1
229	Five years of anti-resorptive effects after 1 or 2 doses of zoledronate " Data from 2 randomized controlled trials. Bone, 2012, 50, S46-S47.	1.4	1
230	What is the appropriate MHRA regulatory response to calcium's increased cardiovascular risk?. BMJ, The, 2013, 346, f3413-f3413.	3.0	1
231	Observational studies"just telling us what we want to hear or telling us where we need to look?. Journal of Bone and Mineral Research, 2013, 28, 980-983.	3.1	1
232	Are trials of vitamin D with mortality as an endpoint really needed?. BMJ, The, 2014, 349, g4452-g4452.	3.0	1
233	Benefits of Calcium Supplements Are Too Small for Clinical Equipose to Exist. Journal of Bone and Mineral Research, 2014, 29, 1914-1915.	3.1	1
234	Vitamin D supplements and bone mineral density " Authors' reply. Lancet, The, 2014, 383, 1293-1294.	6.3	1

#	ARTICLE	IF	CITATIONS
235	Republished: Paget's disease of bone: clinical review and update. Postgraduate Medical Journal, 2014, 90, 328-331.	0.9	1
236	Bone density in healthy men after cessation of calcium supplements: 20-month follow-up of a randomized controlled trial. Osteoporosis International, 2015, 26, 173-178.	1.3	1
237	Maintaining Order in Osteoporosis Treatments. Journal of Bone and Mineral Research, 2017, 32, 1147-1147.	3.1	1
238	Are more trials of calcium supplements really needed?. Osteoporosis International, 2017, 28, 2729-2730.	1.3	1
239	Reader response: Expression of Concern: Does compensatory hyperparathyroidism predispose to ischemic stroke? Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy; An alternative to vitamin D supplementation to prevent fractures in patients with MS; High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology, 2018, 90, 627-628.	1.5	1
240	A closer look at SCOOP: screening for fracture prevention. Lancet, The, 2018, 392, 551-552.	6.3	1
241	Correcting Meta-analyses and Reviews Affected by Retracted Research. JAMA Internal Medicine, 2019, 179, 1005.	2.6	1
242	Evaluating ethics oversight during assessment of research integrity. Research Integrity and Peer Review, 2019, 4, 22.	2.2	1
243	Reporting of absolute risk. BMJ: British Medical Journal, 2010, 341, c6331-c6331.	2.4	1
244	Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ: British Medical Journal, 2010, 341, c6923-c6923.	2.4	1
245	Thyroid ultrasound and nodule malignancy risk: a "real world" assessment of ultrasound reporting and agreement of ultrasound-based malignancy risk estimates with cytology and histology findings. New Zealand Medical Journal, 2020, 133, 20-27.	0.5	1
246	Effective osteoporosis treatments reduce mortality: A meta-analysis. Bone, 2009, 44, S38.	1.4	0
247	Do Calcium Supplements Lead to an Increase in Coronary Calcification?. Heart Lung and Circulation, 2009, 18, S28-S29.	0.2	0
248	Benefits of Vitamin D?. American Journal of Medicine, 2010, 123, e17.	0.6	0
249	Management of primary hyperparathyroidism. Clinical Endocrinology, 2011, 75, 722-722.	1.2	0
250	Vitamin D Supplementation and Fracture Risk—Reply. Archives of Internal Medicine, 2011, 171, 265.	4.3	0
251	Comment: Assessing the Potential Adverse Consequences of Supplemental Calcium on Cardiovascular Outcomes: Should We Change Our Approach to Bone Health?. Annals of Pharmacotherapy, 2012, 46, 1267-1268.	0.9	0
252	Severe Vitamin D Deficiency: A Prerequisite for Chronic Obstructive Pulmonary Disease Responsiveness to Vitamin D Supplementation?. Annals of Internal Medicine, 2012, 156, 904.	2.0	0

#	ARTICLE	IF	CITATIONS
253	Low-Dose Zoledronate in Osteopenic Postmenopausal Women. <i>Obstetrical and Gynecological Survey</i> , 2012, 67, 349-350.	0.2	0
254	Effect of osteoporosis treatment on mortality. <i>Bone</i> , 2012, 50, S27.	1.4	0
255	Convicted at a Show Trial. <i>British Journalism Review</i> , 2013, 24, 19-23.	0.0	0
256	Nonsustained hypercalcaemia and primary hyperparathyroidism in the <sc>PEARS</sc> cohort. <i>Clinical Endocrinology</i> , 2013, 79, 899-899.	1.2	0
257	Authors' reply to McCloskey and colleagues. <i>BMJ, The</i> , 2013, 346, f1440-f1440.	3.0	0
258	Authors' reply to MacDonald and Etminan. <i>BMJ, The</i> , 2014, 349, g5523-g5523.	3.0	0
259	Response to letter to editor. <i>Osteoporosis International</i> , 2014, 25, 2501-2501.	1.3	0
260	Vitamin D and falls – Authors' reply. <i>Lancet Diabetes and Endocrinology, the</i> , 2014, 2, 541.	5.5	0
261	Screening for Vitamin D Deficiency. <i>Annals of Internal Medicine</i> , 2015, 162, 736.	2.0	0
262	Neglect or good practice? Authors'™ reply to letters by Rhein and Degner. <i>BMJ: British Medical Journal</i> , 2017, 356, j716.	2.4	0
263	Enough data to draw conclusions about vitamin D and bone health. <i>BMJ: British Medical Journal</i> , 2018, 363, k4755.	2.4	0
264	Author response: Systematic review and statistical analysis of the integrity of 33 randomized controlled trials. <i>Neurology</i> , 2018, 90, 578-578.	1.5	0
265	Decreased thyroid FNA but increased ultrasound: Is the trade-off worthwhile?. <i>Clinical Endocrinology</i> , 2022, 96, 922-922.	1.2	0
266	Vitamin D Deficiency and Its Health Consequences in New Zealand. , 2010, , 589-601.		0
267	Calcium and cardiovascular risks. <i>Australian Prescriber</i> , 2013, 36, 148-149.	0.5	0
268	Diagnostic category agreement and malignancy rates in clinician-categorised, non-standardised thyroid cytology reports. <i>New Zealand Medical Journal</i> , 2014, 127, 49-55.	0.5	0
269	Participant injury in clinical trials conducted in New Zealand for the benefit of manufacturers: an unfair system?. <i>New Zealand Medical Journal</i> , 2021, 134, 124-131.	0.5	0
270	Vitamin D deficiency, supplementation and testing: have we got it right in New Zealand?. <i>New Zealand Medical Journal</i> , 2021, 134, 86-95.	0.5	0



#	ARTICLE	IF	CITATIONS
271	Nonoperative Management of Mild Primary Hyperparathyroidism: A Reasonable, Evidence-Based Option. Annals of Internal Medicine, 2022, , .	2.0	0